A study published in JAMA Opthamology on July 3 suggested a potential link between a rare eye condition, non-arthritic anterior ischemic optic neuropathy, or NAION, and diabetes patients who take ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.

Nonarteritic anterior ischemic optic neuropathy, or NAION, is a rare condition that afflicts 2 to 10 out of 100,000 people. Like a brain stroke, the condition occurs from reduced blood flow to the ...

Those who take Ozempic or Wegovy may have an increased risk of developing a rare form of blindness, though future research is needed to make a final determination, researchers in a new study said.

While NAION is rare overall, it’s the second most common cause of blindness due to optic nerve damage, according to the scientists. And given the surging popularity of these GLP-1 drugs and much ...

A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.. After ...

Researchers say they have uncovered a link between semaglutide — the active ingredient in Ozempic and Wegovy — and the eye disorder non-arteritic anterior ischemic optic neuropathy.

Among the 710 patients with Type 2 diabetes, the rate of developing NAION was 8.9% for those taking semaglutide, compared to 1.8% for patients taking other medications.

Seven patients experienced NAION-like symptoms; one had papillitis, an inflammation of the optic nerve head; and one developed paracentral acute middle maculopathy, which can cause a blind spot in ...

It found that, over a three-year period, 8.9 percent of diabetes patients using semaglutide were diagnosed with NAION, compared to 1.8 percent of those on another medication.